{"transactions":[{"id":1764691,"issuer":{"id":7145,"kind":"organization","name":"Celularity Inc","symbol":"CELU"},"owners":[{"id":109201,"kind":"organization","name":"Sorrento Therapeutics, Inc.","position":1,"cik":"0000850261","reported_name":"Sorrento Therapeutics, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2023-10-05T17:16:17.000Z","date":"2023-10-05","kind":"sale","planned":false,"acquired":false,"shares":6307158,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 29, 2023, the Reporting Person and Dr. Robert J. Hariri, M.D., Ph. D., (\"Purchaser\") entered into that certain Stock Purchase Agreement (the \"SPA\") pursuant to which the Purchaser agreed (i) to acquire on the date of the signing of the SPA, 9,064,539 shares of Class A common stock (\"Celularity Common Shares\") of Celularity Inc. (\"Celularity\") for an aggregate amount in cash equal to $1.5 million, payable on such initial closing date, and (ii) to acquire, no later than October 4, 2023, the remaining 11,357,585 Celularity Common Shares owned by the Reporting Person for an aggregate amount in cash equal to seventy percent of the 5-Day VWAP of the Celularity Common Shares calculated as of such subsequent closing date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the SPA, the Purchaser paid Sorrento $1.5 million on September 29, 2023. In connection with the transaction described in clause (ii) of footnote 1 above, the Purchaser paid Sorrento $1.0 million on October 5, 2023, as consideration for the transfer of 6,307,158 Celularity Common Shares; however, the transfer of the remaining 5,050,427 Celularity Common Shares in exchange for the $0.8 million of consideration remaining to be paid pursuant to the SPA has not yet been consummated as of the date hereof."}],"balance_after":5050427,"source":{"system":"sec-edgar","filing":"0001104659-23-107259","document":"tm2327884-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/850261/000110465923107259/tm2327884-1_4seq1.xml","form_type":"4"}},{"id":1764690,"issuer":{"id":7145,"kind":"organization","name":"Celularity Inc","symbol":"CELU"},"owners":[{"id":109201,"kind":"organization","name":"Sorrento Therapeutics, Inc.","position":1,"cik":"0000850261","reported_name":"Sorrento Therapeutics, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2023-10-05T17:16:17.000Z","date":"2023-09-29","kind":"sale","planned":false,"acquired":false,"shares":9064539,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 29, 2023, the Reporting Person and Dr. Robert J. Hariri, M.D., Ph. D., (\"Purchaser\") entered into that certain Stock Purchase Agreement (the \"SPA\") pursuant to which the Purchaser agreed (i) to acquire on the date of the signing of the SPA, 9,064,539 shares of Class A common stock (\"Celularity Common Shares\") of Celularity Inc. (\"Celularity\") for an aggregate amount in cash equal to $1.5 million, payable on such initial closing date, and (ii) to acquire, no later than October 4, 2023, the remaining 11,357,585 Celularity Common Shares owned by the Reporting Person for an aggregate amount in cash equal to seventy percent of the 5-Day VWAP of the Celularity Common Shares calculated as of such subsequent closing date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the SPA, the Purchaser paid Sorrento $1.5 million on September 29, 2023. In connection with the transaction described in clause (ii) of footnote 1 above, the Purchaser paid Sorrento $1.0 million on October 5, 2023, as consideration for the transfer of 6,307,158 Celularity Common Shares; however, the transfer of the remaining 5,050,427 Celularity Common Shares in exchange for the $0.8 million of consideration remaining to be paid pursuant to the SPA has not yet been consummated as of the date hereof."}],"balance_after":11357585,"source":{"system":"sec-edgar","filing":"0001104659-23-107259","document":"tm2327884-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/850261/000110465923107259/tm2327884-1_4seq1.xml","form_type":"4"}},{"id":1774282,"issuer":{"id":7345,"kind":"organization","name":"Scilex Holding Co"},"owners":[{"id":109201,"kind":"organization","name":"Sorrento Therapeutics, Inc.","position":1,"cik":"0000850261","reported_name":"Sorrento Therapeutics, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2023-09-25T16:27:57.000Z","date":"2023-09-21","kind":"sale","planned":false,"acquired":false,"shares":4490617,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Stock Purchase Agreement, dated September 21, 2023, between the Reporting Person and Scilex Holding Company (\"Scilex\"), Scilex purchased the following securities from the Reporting Person for an aggregate purchase price of (a) $10 million in cash; plus (b) the assumption by Scilex of $100 million of debt under the Reporting Person's non-amortizing super-priority senior secured debtor-in-possession term loan facility; plus (c) the assumption by Scilex of certain obligations of the Reporting Person for legal fees and expenses in the amount of approximately $12.25 million; plus (d) a credit bid of approximately $23 million owed to Scilex under the Reporting Person's non-amortizing super-priority junior secured term loan facility: (i) 60,068,585 shares of Common Stock of Scilex; (ii) 29,057,097 shares of Series A Preferred Stock of Scilex; and (iii) warrants exercisable for 4,490,617 shares of Common Stock of Scilex."}],"balance_after":0,"derivative":{"exercise_price":11.5,"exercise_date":"2022-11-10","expiration_date":"2027-11-10","underlying":"Common Stock","underlying_shares":4490617},"source":{"system":"sec-edgar","filing":"0001104659-23-103527","document":"tm2326753-1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/850261/000110465923103527/tm2326753-1_4.xml","form_type":"4"}},{"id":1774281,"issuer":{"id":7345,"kind":"organization","name":"Scilex Holding Co"},"owners":[{"id":109201,"kind":"organization","name":"Sorrento Therapeutics, Inc.","position":1,"cik":"0000850261","reported_name":"Sorrento Therapeutics, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-25T16:27:57.000Z","date":"2023-09-21","kind":"sale","planned":false,"acquired":false,"shares":60068585,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Stock Purchase Agreement, dated September 21, 2023, between the Reporting Person and Scilex Holding Company (\"Scilex\"), Scilex purchased the following securities from the Reporting Person for an aggregate purchase price of (a) $10 million in cash; plus (b) the assumption by Scilex of $100 million of debt under the Reporting Person's non-amortizing super-priority senior secured debtor-in-possession term loan facility; plus (c) the assumption by Scilex of certain obligations of the Reporting Person for legal fees and expenses in the amount of approximately $12.25 million; plus (d) a credit bid of approximately $23 million owed to Scilex under the Reporting Person's non-amortizing super-priority junior secured term loan facility: (i) 60,068,585 shares of Common Stock of Scilex; (ii) 29,057,097 shares of Series A Preferred Stock of Scilex; and (iii) warrants exercisable for 4,490,617 shares of Common Stock of Scilex."}],"balance_after":1917210,"source":{"system":"sec-edgar","filing":"0001104659-23-103527","document":"tm2326753-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/850261/000110465923103527/tm2326753-1_4.xml","form_type":"4"}},{"id":2049082,"issuer":{"id":7345,"kind":"organization","name":"Scilex Holding Co"},"owners":[{"id":109201,"kind":"organization","name":"Sorrento Therapeutics, Inc.","position":1,"cik":"0000850261","reported_name":"Sorrento Therapeutics, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-23T16:11:40.000Z","date":"2023-01-19","kind":"other","acquired":false,"shares":73740795,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 19, 2023, the Reporting Person paid its previously announced stock dividend (the \"Dividend\") consisting of an aggregate of 75,999,853 shares of common stock of Scilex Holding Company held by the Reporting Person (the \"Dividend Shares\") to record holders of the Reporting Person's common stock and certain warrants to purchase the Reporting Person's common stock as of January 9, 2023 (the \"Record Date\").  An aggregate of 2,259,058 Dividend Shares are being held in abeyance by the Reporting Person for the benefit of certain holders of warrants to purchase shares of common stock of the Reporting Person who may be entitled to such shares pursuant to the terms of the applicable warrants following the exercise of such warrants, and at the time such shares are distributed to the applicable warrantholders, the Reporting Person will file a Form 4 reporting such distribution."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued form footnote 1) The Reporting Person distributed 0.1410127 of a share of the Issuer's common stock for each share of the Reporting Person's common stock outstanding as of the close of business on the Record Date. The stock ratio was calculated by dividing 76,000,000 by the number of shares of the Reporting Person's common stock and warrants to purchase shares of the Reporting Person's common stock outstanding on the Record Date. No fractional shares were issued in connection with the Dividend and the equityholders of the Reporting Person who were entitled to receive fractional shares of the Dividend Stock received cash (without interest) in lieu of such fractional shares."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 19, 2023, the Reporting Person paid its previously announced stock dividend (the \"Dividend\") consisting of an aggregate of 75,999,853 shares of common stock of Scilex Holding Company held by the Reporting Person (the \"Dividend Shares\") to record holders of the Reporting Person's common stock and certain warrants to purchase the Reporting Person's common stock as of January 9, 2023 (the \"Record Date\").  An aggregate of 2,259,058 Dividend Shares are being held in abeyance by the Reporting Person for the benefit of certain holders of warrants to purchase shares of common stock of the Reporting Person who may be entitled to such shares pursuant to the terms of the applicable warrants following the exercise of such warrants, and at the time such shares are distributed to the applicable warrantholders, the Reporting Person will file a Form 4 reporting such distribution."},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued form footnote 1) The Reporting Person distributed 0.1410127 of a share of the Issuer's common stock for each share of the Reporting Person's common stock outstanding as of the close of business on the Record Date. The stock ratio was calculated by dividing 76,000,000 by the number of shares of the Reporting Person's common stock and warrants to purchase shares of the Reporting Person's common stock outstanding on the Record Date. No fractional shares were issued in connection with the Dividend and the equityholders of the Reporting Person who were entitled to receive fractional shares of the Dividend Stock received cash (without interest) in lieu of such fractional shares."}],"balance_after":61985795,"source":{"system":"sec-edgar","filing":"0000899243-23-002368","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/850261/000089924323002368/doc4.xml","form_type":"4"}},{"id":2099198,"issuer":{"id":7345,"kind":"organization","name":"Scilex Holding Co"},"owners":[{"id":109201,"kind":"organization","name":"Sorrento Therapeutics, Inc.","position":1,"cik":"0000850261","reported_name":"Sorrento Therapeutics, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2022-12-02T19:21:40.000Z","date":"2022-12-02","kind":"purchase","acquired":true,"shares":224841,"price":0.3507,"value":78851.7387,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 8 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.32 to $0.36 per warrant, inclusive. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, full information regarding the number of warrants purchased at each separate price."}],"balance_after":4490617,"derivative":{"exercise_price":11.5,"exercise_date":"2022-11-10","expiration_date":"2027-11-10","underlying":"Common Stock","underlying_shares":224841},"source":{"system":"sec-edgar","filing":"0000899243-22-037521","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/850261/000089924322037521/doc4.xml","form_type":"4"}},{"id":2104654,"issuer":{"id":7345,"kind":"organization","name":"Scilex Holding Co"},"owners":[{"id":109201,"kind":"organization","name":"Sorrento Therapeutics, Inc.","position":1,"cik":"0000850261","reported_name":"Sorrento Therapeutics, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2022-11-25T15:21:39.000Z","date":"2022-11-25","kind":"purchase","acquired":true,"shares":46172,"price":0.4374,"value":20195.6328,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 8 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.37 to $0.45 per warrant, inclusive. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, full information regarding the number of warrants purchased at each separate price."}],"balance_after":4265776,"derivative":{"exercise_price":11.5,"exercise_date":"2022-11-10","expiration_date":"2027-11-10","underlying":"Common Stock","underlying_shares":46172},"source":{"system":"sec-edgar","filing":"0000899243-22-037015","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/850261/000089924322037015/doc4.xml","form_type":"4"}},{"id":2105893,"issuer":{"id":7345,"kind":"organization","name":"Scilex Holding Co"},"owners":[{"id":109201,"kind":"organization","name":"Sorrento Therapeutics, Inc.","position":1,"cik":"0000850261","reported_name":"Sorrento Therapeutics, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2022-11-23T17:59:05.000Z","date":"2022-11-23","kind":"purchase","acquired":true,"shares":442829,"price":0.3967,"value":175670.2643,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 8 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.2444 to $0.45 per warrant, inclusive. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, full information regarding the number of warrants purchased at each separate price."}],"balance_after":4219604,"derivative":{"exercise_price":11.5,"exercise_date":"2022-11-10","expiration_date":"2027-11-10","underlying":"Common Stock","underlying_shares":442829},"source":{"system":"sec-edgar","filing":"0000899243-22-036956","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/850261/000089924322036956/doc4.xml","form_type":"4"}},{"id":2107643,"issuer":{"id":7345,"kind":"organization","name":"Scilex Holding Co"},"owners":[{"id":109201,"kind":"organization","name":"Sorrento Therapeutics, Inc.","position":1,"cik":"0000850261","reported_name":"Sorrento Therapeutics, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to Purchase Common Stock","published_at":"2022-11-22T19:24:39.000Z","date":"2022-11-22","kind":"purchase","acquired":true,"shares":672775,"price":0.226,"value":152047.15,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 8 is a weighted average price. These warrants were purchased in multiple transactions at prices ranging from $0.13 to $0.28 per warrant, inclusive. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or a securityholder of the Issuer, full information regarding the number of warrants purchased at each separate price."}],"balance_after":3776775,"derivative":{"exercise_price":11.5,"exercise_date":"2022-11-10","expiration_date":"2027-11-10","underlying":"Common Stock","underlying_shares":672775},"source":{"system":"sec-edgar","filing":"0000899243-22-036807","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/850261/000089924322036807/doc4.xml","form_type":"4"}},{"id":2117023,"issuer":{"id":7345,"kind":"organization","name":"Scilex Holding Co"},"owners":[{"id":109201,"kind":"organization","name":"Sorrento Therapeutics, Inc.","position":1,"cik":"0000850261","reported_name":"Sorrento Therapeutics, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2022-11-15T18:38:57.000Z","date":"2022-11-10","kind":"other","acquired":true,"shares":307296,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects the assignment and transfer of the warrant to the Reporting Person by Vickers Venture Fund VI (Plan) Ltd (\"Sponsor Two\" and together with Sponsor One, the \"Sponsors\") pursuant the Warrant Transfer Agreement (as described below)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the warrant transfer agreement, dated as of October 12, 2022 (the \"Warrant Transfer Agreement\"), by and among the Reporting Person, the Sponsors, Vickers Vantage Corp. I (\"Vickers\") and Maxim Group LLC, Sponsor One transferred 2,796,704 warrant an aggregate of 3,104,000 warrants to the Reporting Person as over 90% of the public Vickers ordinary shares outstanding as of March 17, 2022 were redeemed in connection with the business combination as further described in Vickers' final prospectus and definitive proxy statement, dated October 28, 2022 (the \"Proxy Statement/Prospectus\") and filed with the Securities and Exchange Commission. The Warrant Transfer Agreement was entered into as consideration for the Reporting Person entering into a letter agreement with Scilex Holding Company (\"Scilex\") pursuant to which the Reporting Party would fund a loan to Scilex upon its request in the maximum aggregate amount of $10,000,000, as further described in the Proxy Statement/Prospectus."}],"balance_after":3104000,"derivative":{"exercise_price":11.5,"exercise_date":"2022-11-10","expiration_date":"2027-11-10","underlying":"Common Stock","underlying_shares":307296},"source":{"system":"sec-edgar","filing":"0000899243-22-035922","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/850261/000089924322035922/doc4.xml","form_type":"4"}},{"id":2117022,"issuer":{"id":7345,"kind":"organization","name":"Scilex Holding Co"},"owners":[{"id":109201,"kind":"organization","name":"Sorrento Therapeutics, Inc.","position":1,"cik":"0000850261","reported_name":"Sorrento Therapeutics, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2022-11-15T18:38:57.000Z","date":"2022-11-10","kind":"other","acquired":true,"shares":2796704,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the assignment and transfer of the warrant to the Reporting Person by Vickers Venture Fund VI Pte Ltd (\"Sponsor One\") pursuant the Warrant Transfer Agreement (as described below)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the warrant transfer agreement, dated as of October 12, 2022 (the \"Warrant Transfer Agreement\"), by and among the Reporting Person, the Sponsors, Vickers Vantage Corp. I (\"Vickers\") and Maxim Group LLC, Sponsor One transferred 2,796,704 warrant an aggregate of 3,104,000 warrants to the Reporting Person as over 90% of the public Vickers ordinary shares outstanding as of March 17, 2022 were redeemed in connection with the business combination as further described in Vickers' final prospectus and definitive proxy statement, dated October 28, 2022 (the \"Proxy Statement/Prospectus\") and filed with the Securities and Exchange Commission. The Warrant Transfer Agreement was entered into as consideration for the Reporting Person entering into a letter agreement with Scilex Holding Company (\"Scilex\") pursuant to which the Reporting Party would fund a loan to Scilex upon its request in the maximum aggregate amount of $10,000,000, as further described in the Proxy Statement/Prospectus."}],"balance_after":2796704,"derivative":{"exercise_price":11.5,"exercise_date":"2022-11-10","expiration_date":"2027-11-10","underlying":"Common Stock","underlying_shares":2796704},"source":{"system":"sec-edgar","filing":"0000899243-22-035922","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/850261/000089924322035922/doc4.xml","form_type":"4"}}]}